Catherine Rea, Thomas York, Ulrike Lorch, Kate Khair, Luke Pembroke, Jigar Amin

New insights from a prospective study on Glanzmann thrombasthenia (GT) have been published in Blood (2023). Led by Catherine Rea, Thomas York, Ulrike Lorch, and their team, this observational study delves into the bleeding patterns and impacts on quality of life (QOL) in 30 GT patients over 3 months. Using a custom-designed electronic bleed diary, the study reveals the high frequency of bleeds and their substantial socioeconomic impacts. Results detail bleed rates, anatomical locations, associated symptoms, and the burden on daily activities. The findings underscore the urgent need for improved treatments to reduce bleed frequency and enhance QOL for GT patients. This study establishes a direct correlation between bleed events and their profound effects on patients' lives, advocating for advancements in GT care.

Latest news

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more

Employee Well-Being: A Commitment that Defines Richmond

October 2, 2023
Dr. Junko Ono, the Occupational Support Manager at Richmond Pharmacology provides her insights on fostering a positive work environment.
Read more


ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event